Abstract
Since nucleos(t)ide analogues (NUC) can lead to rapid reduction in HBV DNA levels in blood and normalization of alanine aminotransferase levels in many patients.
They also provide histological improvement which results in a reduction in liver carcinogenesis. However, it is difficult to completely remove viruses even by NUCs and there are some problems such as emergence of resistant strains and hepatitis relapse resulting from discontinuation of treatment. One of the reasons is that NUCs reduce the HBV DNA level in blood but have almost no effects on the HBV cccDNA level in hepatocyte nuclei which are the origins of HBV replication and HBV cccDNA remains for a long period.
For treatment with NUCs in patients with hepatitis B, it is considered that
NUCs should not be easily discontinued since discontinuation often results in hepatitis relapse. However, it has not been clearly revealed when and how hepatitis relapses after discontinuation. Although there are not a few patients without hepatitis relapse after discontinuation or with mild relapse and finally in a stable condition, it has not been established how to identify such patients efficiently.
We performed research to investigate characteristics of the course after discontinuation of treatment and definition of hepatitis relapse and estimate the relapse rate. "Guidelines for avoiding risks resulting from discontinuation of NUCs 2012," is summarized based on the study results. Because the guidelines are written in Japanese, we explain those in English as a review article.
Introduction
Since nucleos(t)ide analogues (NUC) recently introduced to treatment of hepatitis B strongly inhibit proliferation of HBV, they can lead to rapid reduction in HBV DNA levels in blood and normalization of alanine aminotransferase (ALT) levels in many patients. 1 They also provide histological improvement which results in a reduction in liver carcinogenesis 2, 3 and can be orally administered with few side effects, so they are widely used in clinical practice. However, it is difficult to completely remove viruses even by NUCs and there are some problems such as emergence of resistant strains and hepatitis relapse resulting from discontinuation of treatment. 4 One of the reasons is that NUCs reduce the HBV DNA level in blood but have almost no effects on the HBV cccDNA level in hepatocyte nuclei which are the origins of HBV replication and HBV cccDNA remains for a long period. 5 For treatment with NUCs in patients with hepatitis B, it is considered that NUCs should not be easily discontinued since discontinuation often results in hepatitis relapse. However, it has not been clearly revealed when and how hepatitis relapses after discontinuation. Although there are not a few patients without hepatitis relapse after discontinuation or with mild relapse and finally in a stable condition, it has not been established how to identify such patients efficiently.
We performed research funded by the Health and Labour Sciences Research
Grant to investigate characteristics of the course after discontinuation of treatment and definition of hepatitis relapse and estimate the relapse rate. 6 "Guidelines for avoiding risks resulting from discontinuation of NUCs 2012," is summarized based on the study results (Kanzo 2012; 53: 237-242, The Japan Society of Hepatology). The guidelines don't always recommend discontinuation of NUCs. We determined them to be referred if it is necessary to consider discontinuation due to various reasons.
Serum markers reflecting amount of HBV cccDNA in hepatocytes
The replication process of HBV in hepatocytes is shown in Fig. 1 . HBV is an enveloped DNA virus containing a relaxed circular DNA genome converted into a covalently closed circular DNA (cccDNA) episome in the nucleus of infected cells. [7] [8] [9] [10] These cccDNA molecules serve as transcriptional templates for production of viral 
Aims of these guidelines
These guidelines aim to identify patients with a higher possibility of successful discontinuation or patients who should continue treatments and avoid risks resulting from discontinuation of NUCs as much as possible by establishing indicators for follow-up after discontinuation (Table 1-I) . Successful discontinuation in the guidelines is defined to finally achieve the inactive carrier state with the ALT level of less than 30 IU/L and the HBV DNA level in blood of less than 4.0 log copies/ml. These criteria were defined in compliance with the guidelines for treatment of chronic hepatitis B in Japan. 23 It is known that patients in the inactive carrier state show no progression of hepatic diseases and a reduction in the carcinogenic rate 24, 25 and the criteria are considered to be appropriate.
Requirements to avoid risk of developing severe hepatitis resulting from relapse
It is currently unable to predict hepatitis relapse after discontinuation of NUCs with a sufficient high accuracy. Therefore, we reviewed the risk of developing severe hepatitis and established requirements to prevent severe hepatitis (Table 1-II) . 26 The presence of understanding about the risks of hepatitis relapse and severe hepatitis by both doctors and patients as well as the availability of a follow-up system after discontinuation and appropriate treatment for relapse are the basic essential requirements. Given patients with hepatic cirrhosis or chronic hepatitis with progressed fibrosis similar to cirrhosis can easily develop severe hepatitis and have higher risks of carcinogenesis in the future, we determined that those patients should not easily discontinue NUCs.
Assessment of proliferative potential of HBV and conditions to reduce the relapse risk
It has been experienced that patients with insufficient reduction of HBV DNA level or with HBeAg positive at the time of discontinuation of NUCs can develop hepatitis relapse in higher rate after discontinuation. The tendency was also confirmed scientifically in our study. 6 The cut-off value of HBV DNA level to predict hepatitis relapse was 3.0 log copies/mL by the ROC analysis. Almost all patients with higher HBV DNA levels or with HBeAg positive relapsed within a year while nearly 30% of patients with the HBV DNA levels less than 3.0 log copies/mL and without HBeAg were in the stable condition for a long period. (Fig. 2 ) Based on these results, we included sufficient reduction in HBV DNA levels and HBeAg negative in requirements for discontinuation. We determined the reference range of sufficient reduction in HBV DNA levels in the actual guidelines not to be less than 3.0 log copies /ml but to be negative by real-time PCR in consideration of safety.
Factors relating to hepatitis relapse after discontinuation were analyzed in the population except for patients who were obviously predicted to relapse after discontinuation, or those with the HBV DNA levels of not less than 3.0 log copies/mL or HBeAg positive. The following factors were calculated to be significant; duration of treatment period of NUCs, HBsAg levels at the time of discontinuation, and HBcrAg levels at the time of discontinuation. Since the cut-off value in duration of treatment period was calculated as 16 months, we overestimated and established that NUCs should be discontinued more than 2 years after the initial administration in the guidelines. 6 Two cut-off values were suggested from the results of the ROC analysis for the HBsAg and the HBcrAg levels at the time of discontinuation (Fig. 3 ); 1.9 and 2.9 log IU/ml for the HBsAg level and 3.0 and 4.0 log U/ml for the HBcrAg level. Based on this, HBsAg and HBcrAg levels were scored as shown in Table 1 -III and three groups of the low risk group, the medium risk group and the high-risk group were determined.
The percentage of prediction success was 80% to 90% in the low risk group, approximately 50% in the medium risk group and 10-20% in the high-risk group (Fig.   4 ). In further investigation of factors relating to hepatitis relapse in each group, no factors were newly found in the low and medium risk groups but age was a significant factor in the high-risk group. Although the percentage of prediction success rate is low in the high-risk group (10% to 20%), it resulted slightly higher which was from 30% to 40% with those patients younger than 35 years old. 6 It was interesting to find that the combination of HBsAg and HBcrAg levels were useful in preparing these guidelines for discontinuation. Because productions of HBsAg and HBcrAg are regulated by different promoter and enhance systems of HBV genome, their clinical values vary.
Follow-up method after discontinuation and conditions for retreatment
Follow-up after discontinuation of NUCs includes periodical measurement of HBV DNA levels (real-time PCR) and ALT levels. This study revealed that relapse after discontinuation occurs mostly within a year, gradually decreases after a year and rarely occurs after the first three years of discontinuation. 6 Therefore, we determined it necessary to pay attention especially to relapse immediately after discontinuation. In particular, we determined that it is desirable to follow up patients by blood tests at every two weeks up to 16 weeks after discontinuation and every four weeks after 16 weeks.
One of the important points is what the definition of hepatitis relapse is and
how to follow up after discontinuation. Transient abnormalities in the ALT level or the HBV DNA level may be observed in about two-thirds patients who would finally achieve the inactive carrier state. Therefore, even if the ALT level or the HBV DNA level shows mild elevations, it is possible to follow up without retreatment. However, no criteria have been identified about when to discontinue follow-up and start retreatment. We assessed the transitions of ALT levels and HBV DNA levels after discontinuation of NUCs by the mean and maximum values to identify the criteria.
From this assessment, a strong correlation was shown between the mean and the maximum value in both of them (Fig. 5) . 6 Results of the ROC analysis revealed that the mean ALT of 30 IU/L corresponded to the maximum ALT of 79 IU/L and the mean HBV DNA of 4.0 log copies/ml corresponded to the maximum HBV DNA of 5.7 log copies/ml. Patients with the ALT value of not less than 80 IU/L after discontinuation are highly likely to show the mean value of more than 30 IU/L and not assumed to finally meet the criteria for successful discontinuation. Similarly, Patients with the HBV DNA value of not less than 5.8 log copies/ml after discontinuation are most likely to show the mean value of more than 4.0 log copies/ml and not assumed to meet the criteria for successful discontinuation. Based on these results, we established the condition that patients with the ALT value of not less than 80 IU/L or the HBV DNA level of not less than 5.8 log copies/ml are less likely to finally achieve the inactive carrier state and should be considered retreatment with NUCs. It is considered that NUCs can be discontinued more efficiently and specifically in this condition. Physicians can use more severe criteria at their own discretion in consideration of safety. Less strict criteria can also be used, but it is recommended that the treatment should be done under a certain policy and do not follow the treatment without any aims.
Key points and future issues
This may be the first guideline for discontinuation of NUCs. Most of the data used in this guideline are retrospective and some points remain unsolved. Over 90% of the patients enrolled had genotype C and over 90% of cases were treated with lamivudine until discontinuation. Therefore, key points and future issues are summarized in a section (Table 1-V) . This guideline provides information to support physicians to decide NUCs discontinuation timing but physicians should actually consider for each patient whether NUCs can be discontinued or not because long-term prognosis after NUC discontinuation is not yet clear enough and patients' wishes and physicians' decision need to be prioritized. When NUCs cannot be successfully discontinued, one of the options is re-administration of NUCs. However, it is not investigated whether re-administration of NUCs result the emergence and development of resistant strains. Further, it is not resolved which NUC should be given when re-administration is required. The consent from patients will be necessary on these points.
One of the issues to be investigated in the future is to improve accuracy in predicting hepatitis relapse after discontinuation. Investigations on the following approaches are suggested; higher sensitive HBV DNA , HBV RNA, 12, 13 HBV genotypes and HBV genetic mutations. Since these guidelines were prepared based on retrospective studies, it is necessary to validate them with prospective studies. In addition, how to actively discontinue NUCs by sequential treatment with interferon should also be included as an important issue to be investigated.
Three kinds of NUCs are available now in Japan. Lamivudine is the first NUC introduced into Japan in 2000. Adefovir dipivoxil is used mainly for patients with lamivudine resistance. Entecavir is now recommended as the first choice NUC. Over 10 years have passed since the first NUC became available in Japan and this is the first full-scale guideline for NUC discontinuation. Although this guideline may not be completely sufficient and needs further investigations, this is the first step to start, leading to a better one in the future. 
I. Aims of these guidelines
In treatment with NUCs in patients with chronic hepatitis B, it is one of important treatment goals to aim at drug-free by discontinuation of NUCs. However, discontinuation of
NUCs often results in hepatitis relapse which may become severe. Sufficient consideration must be given to the risk in case of discontinuation.
HBs antigen negative is the goal of treatment with NUCs, but it can't be always achieved easily. Therefore, discontinuation may be considered even if HBs antigen remains positive. These guidelines aim to discontinue NUCs in such conditions and finally achieve the inactive carrier state (ALT<30 IU/L and HBV DNA level in blood<4.0 log copies/ml).
It is currently unknown which of the two options about NUCs, discontinuation or continuation, is effective on life prognosis or liver carcinogenesis. We established these guidelines to be referred in case of considering discontinuation due to various reasons. We aimed to identify patients with a high possibility of successful discontinuation or patients who should inversely continue the treatment and establish indicators for follow-up after discontinuation to avoid risks resulting from discontinuation of NUCs as much as possible.
II. Requirements to avoid risk of developing severe hepatitis resulting from relapse
The following requirements are determined for discontinuation to previously assume and avoid the risk of developing severe hepatitis.
1. Both of the doctor and the patient fully understand the risk of a high frequency of hepatitis relapse that may become severe. 
Requirements for discontinuation of nucleos(t)ide analogues
Almost all patients with high proliferative potential of HBV will relapse after discontinuation. It is essential not to discontinue NUCs in these patients and the requirements were determined as follows:
Requirements for discontinuation ◇ HBV DNA level in blood is negative (real-time PCR) at the time of discontinuation ◇ HBe antigen level in blood is negative at the time of discontinuation
Condition for duration of treatment period of NUCs
Since short-term treatment with NUCs can easily result in relapse, it is recommended to meet the following condition.
Condition for duration of treatment period
◇ More than 2 years after the initial administration of NUCs
Assessment of relapse risk by scoring of viral antigen levels
For the patients who meet the requirements for discontinuation (HBV DNA negative and HBe antigen negative at the time of discontinuation), the HBsAg level and the HBcr antigen level at the time of discontinuation can be scored to predict the relapse risk by the following three groups based on the total score. This risk prediction aims to determine whether NUCs should be discontinued or not by reference to it to reduce the relapse risk. IV. Follow-up method after discontinuation and conditions for retreatment 1. HBV DNA levels (real-time PCR) and ALT levels must be periodically measured after discontinuation of NUCs to pay attention to HBV proliferation and hepatitis relapse resulting from proliferation.
2. Relapse after discontinuation is mostly observed within a year and then gradually decreases.
It is rare to relapse after the first three years. Therefore, it is necessary to pay attention to relapse immediately after discontinuation. In particular, patients should be followed up by blood tests at every two weeks up to 16 weeks after discontinuation and every four weeks after 16 weeks.
3. Transient abnormalities in ALT levels or HBV DNA levels may be observed in about two-thirds patients who successfully discontinued NUCs and would finally achieve the inactive carrier state. Therefore, even if the ALT level or the HBV DNA level shows mild elevations, it is possible to keep following up without retreatment. However, patients who meet the following condition are less likely to finally achieve the inactive carrier state and should be considered retreatment with NUCs.
Condition to consider retreatment with NUCs
◇ ALT ≧ 80 IU/L or HBV DNA ≧ 5.8 log copies/ml after discontinuation V. Key points and future issues 1. The status differs in each patient. Objectives and significance also differ by patient. Thus doctors must determine whether NUCs should be discontinued or not in consideration of those conditions. In case of considering discontinuation, it is recommended to consult with a specialist of hepatic diseases.
2. In case of retreatment with NUCs due to hepatitis relapse after discontinuation, it is unknown whether it results in higher emergence of strains resistant to NUCs or not compared with patients without discontinuation.
3. Since HBV carriers rarely experience hepatitis relapse even in the inactive carrier state (HBV DNA<4.0 log copy/ml and ALT<30 IU/L), they must be followed up after successful discontinuation. Liver carcinogenesis also requires follow-up.
4. The followings are included in future issues; improvement of accuracy in the criteria for discontinuation of NUCs; investigation of the criteria used in these guidelines in a prospective study; and investigation of the way to actively discontinue NUCs using sequential treatment with interferon. 
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